title: Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia.
abstract: Previous studies have shown that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) protect the brain against ischemic injury by upregulating endothelial nitric oxide synthase (eNOS). Here, we tested the hypothesis that statins provide additional beneficial effects by also upregulating endogenous tissue plasminogen activator (tPA) and enhancing clot lysis in a mouse model of embolic focal ischemia. Heterologous blood clots (0.2 mm) were injected into the distal internal carotid artery to occlude blood flow in the middle cerebral artery territory after long-term (14 days) simvastatin, atorvastatin or vehicle treatment. Ischemic lesion volume, neurologic deficits, as well as residual blood clots were measured at 22 h. Reverse transcription-polymerase chain reaction assessed mRNA levels of eNOS, tPA, and the endogenous plasminogen activator inhibitor PAI-1. Ischemic lesion volumes and neurologic deficits were significantly reduced in wild-type mice by both simvastatin and atorvastatin. Statins increased eNOS and tPA mRNA levels but did not change mRNA levels of PAI-1. In eNOS knockout mice, atorvastatin reduced the volume of ischemic tissue and improved neurologic outcomes after arterial occlusion by blood clot emboli. In contrast, statins did not have protective effects in tPA knockout mice after embolic focal ischemia, but only in a filament model where focal ischemia was achieved via mechanical occlusion. These results suggest that statins protect against stroke by multiple mechanisms involving both eNOS and tPA. The involvement of each pathway may be revealed depending on the choice of experimental stroke model.
authors.affiliation: Neuroprotection Research Laboratory, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, 02129, USA.
authors.forename: Minoru
authors.initials: M
authors.lastname: Asahi
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Huang
authors.forename: Sunu
authors.initials: S
authors.lastname: Thomas
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Yoshimura
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Sumii
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Mori
authors.forename: Jianhua
authors.initials: J
authors.lastname: Qiu
authors.forename: Sepideh
authors.initials: S
authors.lastname: Amin-Hanjani
authors.forename: Paul L
authors.initials: PL
authors.lastname: Huang
authors.forename: James K
authors.initials: JK
authors.lastname: Liao
authors.forename: Eng H
authors.initials: EH
authors.lastname: Lo
authors.forename: Michael A
authors.initials: MA
authors.lastname: Moskowitz
mesh_terms: D000818:Animals; D000069059:Atorvastatin; D002545:Brain Ischemia / Q000188:drug therapy* / Q000378:metabolism*; D004195:Disease Models, Animal; D006538:Heptanoic Acids / Q000494:pharmacology; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D020766:Intracranial Embolism / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D018696:Neuroprotective Agents / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000235:genetics / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; D011758:Pyrroles / Q000494:pharmacology; D019821:Simvastatin / Q000494:pharmacology*; D020521:Stroke / Q000188:drug therapy / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000235:genetics / Q000378:metabolism*
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018696:Neuroprotective Agents; D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; C496315:Nos3 protein, mouse; D010959:Tissue Plasminogen Activator
references.citation: Trends Neurosci. 1997 Mar;20(3):132-9
references.pmid: 9061868
references.citation: N Engl J Med. 1996 Oct 3;335(14):1001-9
references.pmid: 8801446
references.citation: JAMA. 1998 May 27;279(20):1643-50
references.pmid: 9613915
references.citation: Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8880-5
references.pmid: 9671773
references.citation: Circ Res. 1998 Oct 5;83(7):683-90
references.pmid: 9758637
references.citation: Arterioscler Thromb Vasc Biol. 2000 Feb;20(2):556-62
references.pmid: 10669656
references.citation: Curr Opin Lipidol. 1999 Dec;10(6):543-59
references.pmid: 10680049
references.citation: J Cereb Blood Flow Metab. 2000 Apr;20(4):709-17
references.pmid: 10779015
references.citation: Nat Med. 2000 Sep;6(9):1004-10
references.pmid: 10973320
references.citation: Circ Res. 2000 Sep 29;87(7):526-8
references.pmid: 11009552
references.citation: Stroke. 2000 Oct;31(10):2442-9
references.pmid: 11022078
references.citation: Stroke. 2001 Apr;32(4):980-6
references.pmid: 11283400
references.citation: Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1712-9
references.pmid: 11701455
references.citation: Br J Pharmacol. 2002 Jan;135(1):284-92
references.pmid: 11786505
references.citation: Thromb Res. 2002 Feb 15;105(4):285-90
references.pmid: 12031821
references.citation: Int J Cardiol. 2002 Nov;86(1):5-18
references.pmid: 12243846
references.citation: J Physiol Pharmacol. 2002 Dec;53(4 Pt 1):503-14
references.pmid: 12512688
references.citation: Stroke. 2003 Feb;34(2):551-7
references.pmid: 12574574
references.citation: Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):156-7
references.pmid: 12588752
references.citation: Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):322-7
references.pmid: 12588778
references.citation: J Cereb Blood Flow Metab. 1997 Oct;17(10):1081-8
references.pmid: 9346433